4D Molecular Therapeutics, Inc. Temporary Equity, Liquidation Preference
4D Molecular Therapeutics, Inc. (FDMT) had Temporary Equity, Liquidation Preference of $0 as of 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Balance Sheet › Temporary Equity › Temporary Equity, Other Disclosure
us-gaap:TemporaryEquityLiquidationPreference · last filed 2022-03-28
- 2020-12-31: Temporary Equity, Liquidation Preference $0.00.
- 2019-12-31: Temporary Equity, Liquidation Preference $108.60M.
| Period end | Temporary Equity, Liquidation Preference |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-25 |
| 2019-12-31 | $108.60M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |